Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
P07355
UPID:
ANXA2_HUMAN
Alternative names:
Annexin II; Annexin-2; Calpactin I heavy chain; Calpactin-1 heavy chain; Chromobindin-8; Lipocortin II; Placental anticoagulant protein IV; Protein I; p36
Alternative UPACC:
P07355; Q567R4; Q6N0B3; Q8TBV2; Q96DD5; Q9UDH8
Background:
Annexin A2, known by various names such as Annexin II and Lipocortin II, is a calcium-regulated membrane-binding protein. It exhibits a high affinity for calcium, significantly enhanced by anionic phospholipids, and binds two calcium ions with high affinity. Annexin A2 plays a crucial role in various cellular processes, including the heat-stress response. It is also known to inhibit PCSK9-enhanced LDLR degradation, potentially reducing PCSK9 protein levels through a translational mechanism and competing with LDLR for PCSK9 binding.
Therapeutic significance:
Understanding the role of Annexin A2 could open doors to potential therapeutic strategies. Its ability to modulate PCSK9-enhanced LDLR degradation suggests a promising avenue for the development of novel treatments for cholesterol-related disorders.